Kedrion, a major name in biopharmaceuticals, crafts plasma-derived medications to treat rare diseases. Following its 2022 merger with UK-based Bio Products Laboratory (BPL), the company has seen vast growth, evolving into a major global participant within a fiercely competitive environment.

In the landscape of pharmaceuticals, supplier management remains vital for success. The landscape is notably complex as firms strive to balance economic sustainability, quality and ethical concerns. In the plasma-derived sector, which Kedrion is part of, synthetic production poses particular challenges.

Read here.